C

킵스파마

256940KOSDAQ의약품 제조업

49.8 / 100

Reference Date: 2026-07-24

Financial Score10.5 / 40
News Sentiment21.3 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 6.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Kipsis Pharma operates three main business segments: OLED equipment development and supply, battery recycling, and pharmaceutical manufacturing and sales. In the OLED segment, the company is expanding its global market through high-precision equipment and FMM mask development. The recycling segment produces lead ingots from recycled batteries for supply to battery manufacturers. Additionally, the biopharma segment is gaining growth momentum through the development of anticancer drugs and digital therapeutics.

Number of Employees

96people

Average Salary

55.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 11.234.0Point
PBR
1.47Industry Average 0.811.0Point

1.8x industry avg (risky)

ROE
-14.33Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
77.31Industry Average 12.430.0Point

6.2x industry avg (risky)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲35.9% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲14.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.8% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 5,970Won52-week high 14,30052-week low 5,390
1-month return4.0Point

1m +6.61% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-07-06